Evidence map›Paper›PMID 41366245›Full record

ArticleNature communications2025

An outer membrane vesicle vaccine prevents lung pathology in a macaque model of pneumonic melioidosis.

Sarah M Baker, Erik W Settles, Kimberly R Celona, Austin B Shannon, Christpher Davitt, Kalen Hall, Aarti Jain, Rafael R de Assis, Anthony E Gregory, Philip L Felgner and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Sarah M Baker *Department of Microbiology and Immunology, School of Medicine, Tulane University, New Orleans, LA, USA. smbaker@uw.edu.ORCID http://orcid.org/0000-0002-0177-8135
Erik W Settles *Pathogen & Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.ORCID http://orcid.org/0000-0003-4331-3683
Kimberly R CelonaPathogen & Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.
Austin B ShannonPathogen & Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.ORCID http://orcid.org/0000-0002-7601-253X
Christpher DavittDepartment of Microbiology and Immunology, School of Medicine, Tulane University, New Orleans, LA, USA.
Kalen HallDepartment of Microbiology and Immunology, School of Medicine, Tulane University, New Orleans, LA, USA.
Aarti JainDepartment of Physiology & Biophysics, School of Medicine, University of California Irvine, Irvine, CA, USA.
Rafael R de AssisDepartment of Physiology & Biophysics, School of Medicine, University of California Irvine, Irvine, CA, USA.
Anthony E GregoryDepartment of Physiology & Biophysics, School of Medicine, University of California Irvine, Irvine, CA, USA.ORCID http://orcid.org/0000-0001-5540-1256
Philip L FelgnerDepartment of Physiology & Biophysics, School of Medicine, University of California Irvine, Irvine, CA, USA.
Celeste WoerleGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Mark MayoGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Bart J CurrieGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.ORCID http://orcid.org/0000-0002-8878-8837
William C WimleyDepartment of Biochemistry and Molecular Biology, School of Medicine, Tulane University, New Orleans, LA, USA.
James B McLachlanDepartment of Microbiology and Immunology, School of Medicine, Tulane University, New Orleans, LA, USA.ORCID http://orcid.org/0000-0001-7741-391X
Heesik YoonSanofi, Sanofi Vaccines, R&D, Orlando, FL, USA.
Chinh T DaoSanofi, Sanofi Vaccines, R&D, Orlando, FL, USA.
Janice MoserSanofi, Sanofi Vaccines, R&D, Orlando, FL, USA.
Derek PociaskDepartment of Medicine, School of Medicine, Tulane University, New Orleans, LA, USA.ORCID http://orcid.org/0000-0002-1256-6410
Paul KeimPathogen & Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.ORCID http://orcid.org/0000-0003-0089-5820
Kasi Russell-LodrigueTulane National Primate Research Center, Covington, LA, USA.ORCID http://orcid.org/0000-0003-3719-0779
Chad J RoyDepartment of Microbiology and Immunology, School of Medicine, Tulane University, New Orleans, LA, USA.ORCID http://orcid.org/0000-0002-1710-6974
Lisa A MoriciDepartment of Microbiology and Immunology, School of Medicine, Tulane University, New Orleans, LA, USA. lmorici@tulane.edu.ORCID http://orcid.org/0000-0002-4799-4941

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
NIH HHS P51 OD011104United States Department of Defense | Defense Threat Reduction Agency (DTRA) HDTRA1-12-C-0022United States Department of Defense | Defense Threat Reduction Agency (DTRA) HDTRA1-14-C-0035United States Department of Defense | Defense Threat Reduction Agency (DTRA) HDTRA1-19-C-0013United States Department of Defense | Defense Threat Reduction Agency (DTRA) HDTRA1-22-C-0013
6 · The paper itself

Abstract

Melioidosis is an emerging infectious disease caused by the intracellular bacterial pathogen, Burkholderia pseudomallei. Infection of humans and animals can occur through multiple routes of bacterial entry resulting in life-threatening pneumonia and/or bacteremia. B. pseudomallei is inherently resistant to multiple antibiotics and mortality rates are high despite therapeutic intervention. Development of an effective vaccine could protect at-risk individuals, such as those who reside in highly endemic areas, military personnel, diabetics, and travelers. Despite decades of pursuit, no candidate vaccine for melioidosis has advanced beyond pre-clinical testing in rodent models. Here, we demonstrate that an outer membrane vesicle (OMV) vaccine prevents pulmonary disease in non human primates (NHP) using survivability, biotelemetry, and clinical pathology assessments. Using two independent serologic assays, we demonstrate that vaccination in rhesus macaques is associated with systemic and mucosal IgG and IgA to OMV surface proteins and polysaccharides. We also show that NHP immune sera promotes opsonophagocytosis by macrophages and that human sera responses to several key OMV antigens are associated with survival in melioidosis. Collectively, these results attest to the potential efficacy of the OMV vaccine and lay the groundwork for its advancement to human phase 1 clinical trials.

Indexed as

Bacterial Outer Membrane ProteinsBacterial VaccinesBurkholderia pseudomalleiLungMelioidosisAnimalsAntibodies, BacterialDisease Models, AnimalFemaleHumansImmunoglobulin AImmunoglobulin GMacaca mulattaMacrophagesMalePhagocytosisAntibodies, BacterialBacterial Outer Membrane ProteinsBacterial VaccinesImmunoglobulin AImmunoglobulin G

Identifiers

PMID41366245
PMCPMC12804674

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.